Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RGDCRAdCOX2F in Pancreatic Adenocarcinoma
NCT06693986Phase 1Recruiting
- Sponsor
- Masonic Cancer Center
- Start
- Dec 2024
- Primary completion
- Oct 2028
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label trial of RGDCRAdCOX2F in pancreatic adenocarcinoma (PDAC) (4 arms), sponsored by Masonic Cancer Center. Primary endpoint: Dose Limiting Toxicity at 2 years. Started Dec 2024; status: recruiting.
02
Drugs
RGDCRAdCOX2F
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06693986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06693986.